Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.46 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 9/20 | 0.45 |
| ▸ | CPB1 | P15086 | 4/20 | 0.45 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | ADA | P00813 | 4/20 | 0.40 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27781554 | 0.90 | CPB2 (0.47) | KDM5AKDM5BCPB2CPB1SMYD3 | |
| SCHEMBL6335415 | 0.85 | SMYD3 (0.52) | CPB2CPB1SMYD3ADA | |
| SCHEMBL710279 | 0.84 | KDM5A (0.54) | KDM5AKDM5BCPB2CPB1SMYD3 | |
| Hydrochloric Acid SCHEMBL28773709 | 0.81 | ADA (0.38) | CPB2CPB1SMYD3ADA | |
| SCHEMBL28309917 | 0.79 | ADA (0.46) | SMYD3ADA | |
| SCHEMBL2282033 | 0.79 | CPB2 (0.45) | KDM5AKDM5BCPB2CPB1SMYD3 | |
| SCHEMBL24842010 | 0.78 | ADA (0.40) | CPB2CPB1SMYD3ADA | |
| SCHEMBL28934829 | 0.78 | NOTUM (0.49) | KDM5AKDM5BCPB2CPB1 | |
| SCHEMBL5521044 | 0.78 | CPB2 (0.42) | CPB2CPB1SMYD3ADA | |
| SCHEMBL24842794 | 0.78 | ADA (0.40) | CPB2CPB1SMYD3ADA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101679293-A | Urocanic acid derivatives useful for the treatment of immune-related and inflammatory diseases | VALETTA HEALTH B V | 2010-03-24 | — | — | CN | disclosed |
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-17 | — | — | US | disclosed |
| US-6960601-B2 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | GPR119, GIPR, PGC | KDM5A 486/4885KDM5B 339/4885CPB2 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.